insurers proposal conceptual stage spark allow insurers spread payments luxturna multiple years far price structures pay price think pretty line seeing innovative therapies said dr. stuart orkin pediatric oncologist dana farber cancer institute boston children hospital cited car t therapies cancer cost hundreds thousands dollars newfangled immuno oncology treatments similar price tags question orkin written extensively society pay gene therapy spark determines individual patient treated luxturna failed merits rebate applaud thinking payment schemes orkin said better price said know paying food drug administration approved luxturna december treat people type inherited retinal disease caused mutation gene called rpe65 people born mutated